Moderna-Merck melanoma vaccine cuts recurrence risk 42% in full trial data

Full phase 3 data show Moderna and Merck's personalized mRNA shot cut melanoma relapse risk 42%, but survival data are immature.

Objective Facts

Moderna and Merck's personalized mRNA cancer vaccine, intismeran autogene, given with Merck's Keytruda after surgery, lowered the risk of melanoma recurrence or death by 42% compared with Keytruda alone in the phase 3 INTerpath-001 trial, according to data presented by Georgina Long at the ESMO Congress in Madrid on October 24, 2026. The trial enrolled 1,137 patients with stage IIB to IV melanoma; at two years, 82.2% of the vaccine group and 70.0% of the control group were alive without recurrence, CancerNetwork reported. Overall survival was not significantly different yet, with a median follow-up of 24.6 months. The data came out two days early after a leak, and Moderna's stock fell sharply as investors weighed results that BioPharma Dive said landed at the low end of Wall Street's expectations.

Deep Dive

Moderna and Merck first said in August that INTerpath-001 met its main goal, and AJMC reported then that it was the first positive late-stage result for an mRNA cancer treatment. Each dose is built from a patient's own tumor: the tumor is sequenced and up to 34 tumor-specific targets are encoded in mRNA, according to AJMC. The full numbers arrived in Madrid. CancerNetwork reported a hazard ratio of 0.58 for recurrence-free survival, with the benefit appearing after about six months (hazard ratio 0.42 beyond that point, 0.99 before it). Fever and injection site pain were far more common with the vaccine, but serious treatment-related side effects were similar in both arms, and no deaths were tied to intismeran. The results drew two very different readings. Clinicians welcomed them: Long said more time free of melanoma is a meaningful benefit in its own right, per News-Medical, and Eva Munoz Couselo of Vall d'Hebron Institute of Oncology in Barcelona called the findings a major breakthrough while asking for longer follow-up, according to Science Media Centre Spain. Investors focused on the gaps. BioPharma Dive reported that the 38% cut in distant spread was smaller than the earlier phase 2 study suggested, and RBC Capital Markets analyst Trung Huynh wrote that commercial success is far less certain than approval. William Blair's Myles Minter described a sell-the-news reaction, while TD Cowen's Tyler Van Buren said the data cleared the bar for a practice-changing result. STAT reported that Moderna had more than tripled since August before the drop, which helps explain the size of the selloff. ESMO's James Larkin also stressed, per News-Medical, that this is a treatment for people who already have cancer, not a shot that prevents cancer in healthy people. The main open question is survival. Overall survival data are immature and did not meet the prespecified threshold, CancerNetwork reported, so later readouts will show whether fewer relapses mean longer lives. Regulators are next: the companies are in talks with agencies, and the paper is headed to The New England Journal of Medicine. Manufacturing a custom product for each patient is another hurdle; Marisol Soengas of Spain's CNIO said the challenge is scaling that personalization, according to Science Media Centre Spain, and 17.3% of screened patients were excluded for inadequate tumor samples, CancerNetwork reported. The result also lands while federal health officials are cool on mRNA: Newsweek reported that HHS under Robert F. Kennedy Jr. moved in 2025 to wind down 22 mRNA vaccine projects for respiratory infections, a decision HHS said did not cover other uses.

OBJ SPEAKING

Create StoryTimelinesVoter ToolsRegional AnalysisPolicy GuideAll StoriesCommunity PicksUSWorldPoliticsBusinessHealthEntertainmentTechnologyAbout

Moderna-Merck melanoma vaccine cuts recurrence risk 42% in full trial data

Full phase 3 data show Moderna and Merck's personalized mRNA shot cut melanoma relapse risk 42%, but survival data are immature.

Oct 25, 2026· Updated Oct 26, 2026
What's Going On
  • Georgina Long of Melanoma Institute Australia presented the phase 3 INTerpath-001 results at the ESMO Congress in Madrid on October 24, 2026, according to CancerNetwork and News-Medical.
  • Among 1,137 patients who had surgery for stage IIB to IV melanoma, adding intismeran autogene to Keytruda cut the risk of recurrence or death by 42% (hazard ratio 0.58); 82.2% were recurrence-free at two years versus 70.0% on Keytruda alone.
  • Risk of distant spread or death fell 38%, but the overall survival difference (hazard ratio 0.77) was not statistically significant because the data are still immature.
  • ESMO released the data early on October 22 after results leaked online, and Moderna shares fell 17.6% that day, according to STAT as republished by The Boston Globe; BioPharma Dive reported a drop of nearly 25%.
  • The results have been accepted by The New England Journal of Medicine, and the companies are talking with regulators, CancerNetwork reported.
◆ All Sources (8)
CancerNetwork - INTerpath-001 Data Detail Survival, Subgroup, and Safety Findings in MelanomaNews-Medical - Personalized mRNA cancer vaccine cuts melanoma recurrence risk when added to immunotherapyThe Boston Globe (from STAT) - Moderna stock plummets even after data confirm cancer vaccine with Merck met key endpoints in melanoma trialBioPharma Dive - Moderna, Merck shares fall on eagerly anticipated cancer vaccine resultsEndpoints News - #ESMO26: Merck and Moderna's cancer vaccine data were 'a triumph of science.' And now, the work beginsScience Media Centre Spain - The results of the personalised melanoma vaccine will be presented at the European Congress of Medical OncologyAJMC - Moderna, Merck mRNA Cancer Vaccine Succeeds in Late-Stage TrialNewsweek - Moderna, Merck stock, mRNA cancer, Trump and RFK Jr. (Aug. 19, 2026)
Objective Deep Dive

Moderna and Merck first said in August that INTerpath-001 met its main goal, and AJMC reported then that it was the first positive late-stage result for an mRNA cancer treatment. Each dose is built from a patient's own tumor: the tumor is sequenced and up to 34 tumor-specific targets are encoded in mRNA, according to AJMC. The full numbers arrived in Madrid. CancerNetwork reported a hazard ratio of 0.58 for recurrence-free survival, with the benefit appearing after about six months (hazard ratio 0.42 beyond that point, 0.99 before it). Fever and injection site pain were far more common with the vaccine, but serious treatment-related side effects were similar in both arms, and no deaths were tied to intismeran.

The results drew two very different readings. Clinicians welcomed them: Long said more time free of melanoma is a meaningful benefit in its own right, per News-Medical, and Eva Munoz Couselo of Vall d'Hebron Institute of Oncology in Barcelona called the findings a major breakthrough while asking for longer follow-up, according to Science Media Centre Spain. Investors focused on the gaps. BioPharma Dive reported that the 38% cut in distant spread was smaller than the earlier phase 2 study suggested, and RBC Capital Markets analyst Trung Huynh wrote that commercial success is far less certain than approval. William Blair's Myles Minter described a sell-the-news reaction, while TD Cowen's Tyler Van Buren said the data cleared the bar for a practice-changing result. STAT reported that Moderna had more than tripled since August before the drop, which helps explain the size of the selloff. ESMO's James Larkin also stressed, per News-Medical, that this is a treatment for people who already have cancer, not a shot that prevents cancer in healthy people.

The main open question is survival. Overall survival data are immature and did not meet the prespecified threshold, CancerNetwork reported, so later readouts will show whether fewer relapses mean longer lives. Regulators are next: the companies are in talks with agencies, and the paper is headed to The New England Journal of Medicine. Manufacturing a custom product for each patient is another hurdle; Marisol Soengas of Spain's CNIO said the challenge is scaling that personalization, according to Science Media Centre Spain, and 17.3% of screened patients were excluded for inadequate tumor samples, CancerNetwork reported. The result also lands while federal health officials are cool on mRNA: Newsweek reported that HHS under Robert F. Kennedy Jr. moved in 2025 to wind down 22 mRNA vaccine projects for respiratory infections, a decision HHS said did not cover other uses.

◈ Tone Comparison

Medical outlets framed the data as a clinical milestone, with Endpoints News carrying the phrase "a triumph of science" in its headline. Financial coverage was cooler: STAT, in a story republished by The Boston Globe, said Moderna's stock "plummets" despite the trial meeting its goals.